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atric or adolescent cases have yet been reported. An 18-year-old female was diagnosed with B-
cell precursor acute lymphoblastic leukemia at the age of 10 years. Our patient received three
allogeneic hematopoietic stem cell transplantations but experienced hematological relapse af-
ter each. She received combination therapy of prednisolone, L-asparaginase, vincristine, and
bortezomib after the third relapse. On Day 16 after the initiation of chemotherapy, she devel-
oped NOMI; therefore, we performed a right-sided hemicolectomy on Day 27. Nonocclusive
mesenteric ischemia should be considered during the differential diagnosis of intestinal com-
plications after chemotherapy, even in pediatric and adolescent patients.
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Nonocclusive mesenteric ischemia (NOMI) is induced by in-
testinal vasospasm without thromboembolic occlusion. The
typical patient with NOMI is critically ill with severe cardiac
disease or sepsis while undergoing inotropic support.1,2
Thus, NOMI is associated with high morbidity and mortal-
ity rates.3 The estimated overall incidence of autopsy-
verified fatal NOMI is 2.0 cases/100,000 person-years,1
although no pediatric or adolescent cases have yet been
reported. In this paper, we report a case of NOMI occurring
in an adolescent girl after being administered chemo-
therapy for a third hematological relapse of acute
lymphoblastic leukemia (ALL).2. Case report
An 18-year-old woman had been diagnosed with B-cell pre-
cursor ALL in March 2005 at the age of 10 years. Because of
marked leukocytosis (191  109/L) and a poor response to
prednisolone monotherapy for 7 days, we selected the L04-
16 protocol of the Tokyo Children’s Cancer Study Group to
estimate the risk associated with allogeneic hematopoietic
stem cell transplantation (allo-HSCT). In August 2005, she
achieved complete remission after induction therapy and
then received an allogeneic bone marrow transplant from
her human leukocyte antigen (HLA)-matched mother; she
had been administered a preparative regimen comprising 8-
Gy of total body irradiation, cyclophosphamide at 120 mg/
kg, and fludarabine at 150 mg/m2. In July 2006, she expe-
rienced her first relapse. Chemotherapy and donor
lymphocyte infusion were administered, but the patient
failed to achieve complete remission. In July 2007, she
received an allogeneic peripheral blood stem cell transplant
from her mother, after conditioning with cytarabine at 10 g/
m2, idarubicin at 36 mg/m2, cyclophosphamide at 120 mg/
kg, and fludarabine at 150 mg/m2. However, she experi-
enced a second relapse in October 2008. In December 2008,
she received a third allo-HSCT a transplant from a sibling
with one HLA allele mismatch during the active disease,
after she had been conditioned with busulfan at 12.8 mg/kg,
cyclophosphamide at 120 mg/kg, and fludarabine at 150mg/
m2. In September 2009, she developed type 2 diabetes
mellitus. After her third relapse in August 2012, she received
a combination therapy of prednisolone, L-asparaginase,
vincristine, and bortezomib, beginning on September 19,
2012 (Day 1, Figure 1). Physical examination and laboratory
findingsdwhich included blood, urine, echocardiography,
thoracoabdominal contrast-enhanced computed tomogra-
phy (CT), and brain magnetic resonance imagingdwereDays after initiation of chemotherapy 1 2 3 4 5
Prednisolone 30 mg/m2/day
Bortezomib 1.3 mg/m2/day
L-asparaginase 6,000 U/m2/day
Vincristine 1.5mg/m2/day
Figure 1 Chemotherapy regimen aft
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She received a continuous infusion of insulin after starting
chemotherapy. During chemotherapy, onlymild neutropenia
(500‒1000/mL) was present and her general status was
relatively good. After the initiation of chemotherapy, the
blast count in peripheral blood decreased and disappeared
by Day 16. Because of the continuous drip infusion before
beginning chemotherapy, she did not develop severe dehy-
dration. However, she often required furosemide to main-
tain sufficient urine flow during chemotherapy. She
complained of severe abdominal pain on Day 16. Contrast-
enhanced CT showed thickening of the bowel wall,
decreased bowel wall enhancement by contrast media, an
elevated CT value around the ascending colon, and accu-
mulation of ascitic fluid (Figure 2A). No obvious thrombo-
embolic occlusion of themesenteric arteries was evident. An
exploratory laparotomy revealed extreme edema of the
bowel wall from the ileum to the ascending colon. Pulsation
of the ileocolic, right colic, and middle colic arteries was
clearly palpable. No bacterial pathogens were detected by
cultures of feces and ascitic fluid. Because no macroscopi-
cally abnormal intestinal lesions were detected, we decided
only to insert an indwelling drainage catheter. However,
because her abdominal pain persisted, we again performed
abdominal contrast-enhanced CT on Day 27, which revealed
thinning of the large bowel without enhancement of the
mucosa (Figure 2B). These findings strongly suggested ne-
crosis of the ascending colon; therefore, we performed a
right-sided hemicolectomy. Surgical findings confirmed ne-
crosis from the ileum to the ascending colon (Figure 3A).
Blood flow within the ileocolic artery that supplied the
necrotic colon was confirmed. The colonic mucosa adjacent
to the necrotic lesions was characterized by decreased
crypts with reduced goblet cells. Furthermore, bleeding to
the lamina propria, congestion, edema, and ectasia of the
submucosa were present. These findings indicated chronic
ischemia of the colon (Figure 3B). There were no findings of
vascular lesions, leukemia, arteriosclerosis, or graft-versus-
host disease (GVHD). We diagnosed NOMI because there
were no findings of vascular lesions, invasion of leukemia
cells, or GVHD by contrast-enhanced CT, pathological ex-
amination, or surgical findings. No further abdominal com-
plications occurred after restarting chemotherapy. In April
2013, she received unrelated cord blood transplantation. In
June 2013, she died of invasive aspergillosis.
3. Discussion
In this paper, we reported a case of an adolescent patient
who developed NOMI after chemotherapy for a third6 7 8 9 10 11 12 13 14 15 16
er the third hematological relapse.
Mesenteric Ischemia after Chemotherapy in an Adolescent Patient
splantations for Acute Lymphoblastic Leukemia, Pediatrics and
Figure 2 Abdominal contrast-enhanced computed tomography (CT) on Days 16 and 27. (A) In the ascending colon, thickening of
the bowel wall, decreased bowel wall enhancement by contrast media (arrow), an elevated CT value around the colon, and
accumulation of ascitic fluid are present. There is no obvious thromboembolic occlusion of the mesenteric arteries. (B) The bowel
wall is thinner, but the mucosa is not enhanced (arrowheads).
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infection, hematoma, the use of chemotherapeutic agents,
and/or GVHD may have caused colonic complications in this
patient. Infection, hematoma, and GVHD were excluded by
blood tests, imaging, bacterial culture, and pathological
findings. Because there have been no reports of necrosis of
the large sections of the colon after the administration of
chemotherapeutic agents, we excluded chemotherapeutic
agents as the cause of colonic necrosis in our patient.
Because no arterial thromboembolic occlusion was
observed by contrast-enhanced CT imaging, surgical find-
ings, or pathological examination, we diagnosed NOMI inFigure 3 Pathological findings of the ascending colon. (A) The re
ileum to the ascending colon, which is indicative of colonic necro
lesions has decreased crypts with reduced goblet cells. There is ble
congestion, edema, and ectasia (arrow). These findings indicate ch
lesions, leukemia, arteriosclerosis, or graft-versus-host disease.
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particularly sensitive to NOMI because this site frequently
lacks a well-developed and consistent marginal collateral
vascular network.4 In addition, right colonic involvement is
associated with a particularly poor prognosis.5,6
A large proportion of patients with NOMI reportedly
develop severe complications such as congestive heart
failure, sepsis, myocardial infarction, and renal/hepatic
disease.1 The use of digitalis, emulgents, and beta-blockers
is also a risk factor for NOMI. Because our patient received
furosemide to maintain sufficient urine flow during
chemotherapy, we could not exclude the possibility thatsected sample reveals a green-tinged intestinal tract from the
sis (arrow). (B) The colonic mucosa adjacent to the necrotic
eding to lamina propria (arrowheads). The submucosa exhibits
ronic ischemia of the colon. There are no findings of vascular
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that long-term survivors after allo-HSCT were likely to have
an increased risk of premature cardiovascular accidents.
Therefore, dysfunction of the mesenteric arteries caused
by multiple allo-HSCT may have a role in the development
of NOMI.
Mitsuyoshi et al3 and Kamimura et al8 report that early
treatment with prostaglandin E1 can effectively increase
survival in patients with NOMI. Therefore, if our patient had
been diagnosed with NOMI at the onset of abdominal pain
and received prostaglandin E1 therapy, the development of
colonic necrosis could have been avoided. However, NOMI is
difficult to diagnose in the early phase because it lacks
clear clinical symptoms. Selective digital subtraction angi-
ography of the mesenteric arteries is the gold standard for
the diagnosis of NOMI. Multidetector CT is also capable of
depicting the condition of the arteries in sufficient detail to
enable an early diagnosis of NOMI.3,8 In retrospect, we
should have performed digital subtraction angiography
and/or multidetector CT to diagnose NOMI because
thromboembolic occlusion of the mesenteric arteries was
not detected at the onset of abdominal pain.
In conclusion, NOMI should be considered during differ-
ential diagnosis of intestinal complications, even in pedi-
atric and adolescent patients when there is no apparent
thromboembolic occlusion of the mesenteric arteries.
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